- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01751646
Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART
A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Effectiveness of Vitamin D3 50,000 IU Every 4 Weeks to Increase Bone Mineral Density and Decrease Tenofovir-Induced Hyperparathyroidism in Youth With HIV Infection Being Treated With Tenofovir-Containing Combination Antiretroviral Therapy (cART)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a 48 week randomized double-blind, placebo-controlled prospective cohort study of adolescents and young adults with HIV infection in the ATN who are currently being treated with cART that includes TDF as one component of the regimen that includes at least three Food and Drug Administration (FDA)-approved ARVs for at least 180 days. Subjects must have at least one documented viral load that is below 200 copies/mL that is collected following initiation of TDF containing cART and greater than 90 days prior to randomization; no viral load above 200 copies/mL if measured within the 90 days prior to randomization; and an HIV viral load obtained at screening that is below 200 copies/mL.
Treatment assignments will be balanced by subject sex at birth, age (<20 years vs. >=20 years), and race (African American vs. other). Enrolled subjects will be randomized to receive vitamin D3 50000 IU or matching placebo, given orally every four weeks by DOT. In addition to the randomized study agent, all subjects will receive a MVI to be taken orally once daily. This "standard" MVI will contain ingredients not to exceed 600 IU of vitamin D3 and 200 mg Ca.
Dual energy x-ray absorptiometry (DXA) measurement of bone mineral content (BMC)/bone mineral density (BMD) of whole body, spine, and hip, will be performed at baseline and study weeks 24 and 48. Blood and urine sampling to assess the Ca-phosphorous (PO4) axis, parathyroid hormone (PTH)-FGF23-vitamin D signaling, bone turnover, and renal glomerular and tubular function will occur at baseline and study weeks 12, 24, and 48. Blood samples to measure Gluc homeostasis will be drawn at baseline and week 48, and will be run by batch analysis.
Safety, measured by serum calcium (SCa) and serum creatinine (SCr), will be monitored by subject's record review at study sites since these labs will generally be measured as a part of routine clinical care. The Adolescent Medicine Trials Network for HIV/AIDS Interventions 109 (ATN 109) study will use the SCa and SCr values obtained within 10 weeks at the time of the visit beginning at the baseline visit. If these evaluations were not performed within the prior 10 weeks they will be drawn at the time of each visit. Viral load and cluster of differentiation 4 (CD4) cell count results will be recorded for this study, ATN 109, at screening, baseline and study weeks 12, 24, 48, and Post-Week 48 provided the evaluations were done within the protocol specified timeframe. If the evaluations were not performed within the protocol specified timeframes they will be drawn at the time of the visit.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
San Juan, Puerto Rico, 00936-5067
- San Juan City Hospital (Puerto Rico) - NICHD Westat Site
-
-
-
-
California
-
Los Angeles, California, United States, 90027
- Children's Hopsital of Los Angeles
-
Los Angeles, California, United States, 90033
- University of Southern California - NICHD Westat Site
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Childrens National Medical Center
-
-
Florida
-
Fort Lauderdale, Florida, United States, 33316
- Children's Diagnostic and Treatment Center - NICHD Westat Site
-
Miami, Florida, United States, 33101
- University of Miami School of Medicine
-
Tampa, Florida, United States, 33606
- University of South Florida
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Stroger Hospital and the CORE Center
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Tulane Medical Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins University
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins University - NICHD Westat Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Fenway Institute
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Wayne State University
-
-
New York
-
Bronx, New York, United States, 10467
- Montefiore Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Children's Hospital of Philadelphia
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- St. Jude Childrens Research Hospital
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
To be considered eligible for enrollment, an individual must meet the criteria listed below at the time of randomization:
NOTE: If the DXA scan is scheduled prior to randomization, all eligibility criteria must be met prior to performing the DXA scan.
- Age 16 years and 0 days to 24 years and 364 days;
- Behaviorally infected with HIV (e.g., sexual contact, injection drug use; not infected by perinatal transmission, blood transfusion, or at age younger than 9 years);
HIV-1 infection as documented in subject's medical record by at least one of the following criteria:
- reactive HIV screening test result with an antibody based FDA-licensed assay followed by a positive supplemental assay (e.g., HIV-1 Western Blot, HIV-1 Indirect Immunofluorescence, Antibody Differentiation Assay (Multispot)); or
- positive HIV-1 DNA polymerase chain reaction (PCR) assay; or
- plasma HIV-1 quantitative RNA assay >1,000 copies/mL; or
- positive plasma HIV-1 RNA qualitative assay
- Subjects must have at least one documented HIV viral load that is below 200 copies/mL collected following initiation of TDF containing cART and greater than 90 days prior to randomization; no HIV viral load above 200 copies/mL if measured within the 90 days prior to randomization; and an HIV viral load obtained at screening that is below 200 copies/mL.
- Currently being treated for at least 180 days by the time of randomization with a TDF containing cART with at least 2 other FDA approved ARVs (NOTE: This may include a TDF-containing fixed drug combination medication);
- Negative serum hepatitis B surface antigen (HBsAg) at screening or by history within 4 weeks prior to screening (see section 7.1.3);
- Willingness and ability to remain on the same cART regimen for the duration of study participation;
- Willingness and ability to participate in the study, follow all study procedures for the duration of study participation, and provide written informed consent or assent with parental permission, if applicable; and
- For females of child-bearing potential, agreement to use a minimum of one proven-effective method of birth control and willingness to postpone pregnancy for the duration of study participation (see section 5.3.2 for permitted hormonal contraceptives)
Exclusion Criteria:
To be considered eligible for enrollment, an individual must not meet any of the criteria listed below at the time of randomization:
NOTE: If the DXA scan is scheduled prior to randomization, all eligibility criteria must be met prior to performing the DXA scan.
- Prior hypersensitivity to vitamin D;
- History of sarcoidosis, arteriosclerosis, renal stones, glomerulonephritis, interstitial kidney disease, nephrotic syndrome, hypercalcemia, osteoporosis and/or other bone diseases, clinical diagnosis of hypoparathyroidism or hyperparathyroidism;
- Lactation or pregnancy currently or within the past 24 weeks;
- Chemotherapy or radiation therapy for malignancy within the past 12 months;
- Known presence of GI disease that, in the opinion of the clinician, would interfere with study agent administration or absorption (e.g. Crohn's, Colitis);
- For subjects ≥ 18 years, confirmed creatinine clearance < 70 ml/min (estimated glomerular filtration rate (GFR) from SCr using Cockcroft and Gault (CG) equation) and for subjects <18 years, confirmed creatinine clearance < 70ml/min/1.73m2 (estimated GFR from SCr using Schwartz formula (see section 3.5). (Estimated GFR may be calculated using the formulae programmed on the ATN website);
- SCa > Upper Limit Normal (ULN) for local laboratory values (see section 7.1.3);
- Active Grade 3 or higher clinical or laboratory toxicity except atazanavir (ATV) associated indirect hyperbilirubinemia (see section 9.5.2.2);
- Weight is > 350 pounds (lbs) or 159 kilograms (kgs);
- Positive hepatitis C antibody by history or at screening (see section 7.1.3); and
- Use of any medications as specified in sections 5.3.1, 5.3.3 and 5.4.
- Females Only: Use of certain hormonal contraceptives as specified in the protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A: Vitamin D3 50,000 IU
Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT).
In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca).
Subjects will self-administer one MVI tablet orally once daily.
|
Group A: Vitamin D3 50,000 IU orally every four weeks by DOT
Other Names:
|
Placebo Comparator: Group B: Vitamin D3 placebo
Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT.
In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca.
Subjects will self-administer one MVI tablet orally once daily.
|
Group B: Vitamin D3 placebo orally every four weeks by DOT
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change From Baseline to Week 48 in Dual Energy X-ray Absorptiometry (DXA)-Measured BMD at the Spine for the Randomized Study Groups
Time Frame: Baseline and wk 48
|
Percent change from baseline to week (wk) 48 in DXA-measured BMD at the spine for the randomized study groups. Lumbar spine BMD (L1 - L4) (g/cm2) change from Baseline to wk 48 visit. |
Baseline and wk 48
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change From Baseline to Week 24 of BMC of Whole Body for the Randomized Study Groups
Time Frame: Baseline and week 24
|
Baseline and week 24
|
|
Percent Change From Baseline to Week 48 of BMC of Whole Body for the Randomized Study Groups
Time Frame: Baseline and week 48
|
Baseline and week 48
|
|
Percent Change From Baseline to Week 24 of Lumbar Spine (L1-L4) BMD for the Randomized Study Groups
Time Frame: Baseline and week 24
|
Baseline and week 24
|
|
Change From Baseline to Week 24 of Lumbar Spine (L1-L4) BMD Z-score for the Randomized Study Groups
Time Frame: Baseline and week 24
|
The Z-score is the standard deviation around mean bone mineral density in the lumbar spine, adjusted for sex, age, and race/ethnicity.
An average Z-score of zero would be expected to be seen in healthy populations.
A negative Z-score indicates lower than average bone mineral density.
Low bone mineral density is a frequent finding in HIV-infected individuals, including adolescents and young adults.
|
Baseline and week 24
|
Change From Baseline to Week 48 of Lumbar Spine (L1-L4) BMD Z-score for the Randomized Study Groups
Time Frame: Baseline and week 48
|
The Z-score is the standard deviation around mean bone mineral density in the lumbar spine, adjusted for sex, age, and race/ethnicity.
An average Z-score of zero would be expected to be seen in healthy populations.
A negative Z-score indicates lower than average bone mineral density.
Low bone mineral density is a frequent finding in HIV-infected individuals, including adolescents and young adults.
|
Baseline and week 48
|
Percent Change From Baseline to Week 24 of Femoral Neck BMD for the Randomized Study Groups
Time Frame: Baseline and week 24
|
Baseline and week 24
|
|
Percent Change From Baseline to Week 48 of Femoral Neck BMD for the Randomized Study Groups
Time Frame: Baseline and week 48
|
Baseline and week 48
|
|
Change From Baseline to Week 24 of Femoral Neck BMD Z-score for the Randomized Study Groups
Time Frame: Baseline and week 24
|
The Z-score is the standard deviation around mean bone mineral density in the femoral neck, adjusted for sex, age, and race/ethnicity.
An average Z-score of zero would be expected to be seen in healthy populations.
A negative Z-score indicates lower than average bone mineral density.
Low bone mineral density is a frequent finding in HIV-infected individuals, including adolescents and young adults.
|
Baseline and week 24
|
Change From Baseline to Week 48 of Femoral Neck BMD Z-score for the Randomized Study Groups
Time Frame: Baseline and week 48
|
The Z-score is the standard deviation around mean bone mineral density in the femoral neck, adjusted for sex, age, and race/ethnicity.
An average Z-score of zero would be expected to be seen in healthy populations.
A negative Z-score indicates lower than average bone mineral density.
Low bone mineral density is a frequent finding in HIV-infected individuals, including adolescents and young adults.
|
Baseline and week 48
|
Percent Change From Baseline to Week 24 of Total Hip BMD for the Randomized Study Groups
Time Frame: Baseline and week 24
|
Baseline and week 24
|
|
Percent Change From Baseline to Week 48 of Total Hip BMD for the Randomized Study Groups
Time Frame: Baseline and week 48
|
Baseline and week 48
|
|
Change From Baseline to Week 24 of Total Hip BMD Z-score for the Randomized Study Groups
Time Frame: Baseline and week 24
|
The Z-score is the standard deviation around mean bone mineral density in the total hip, adjusted for sex, age, and race/ethnicity.
An average Z-score of zero would be expected to be seen in healthy populations.
A negative Z-score indicates lower than average bone mineral density.
Low bone mineral density is a frequent finding in HIV-infected individuals, including adolescents and young adults.
|
Baseline and week 24
|
Change From Baseline to Week 48 of Total Hip BMD Z-score for the Randomized Study Groups
Time Frame: Baseline and week 48
|
The Z-score is the standard deviation around mean bone mineral density in the total hip, adjusted for sex, age, and race/ethnicity.
An average Z-score of zero would be expected to be seen in healthy populations.
A negative Z-score indicates lower than average bone mineral density.
Low bone mineral density is a frequent finding in HIV-infected individuals, including adolescents and young adults.
|
Baseline and week 48
|
Change in SCr From Baseline to Week 12.
Time Frame: Baseline and week 12
|
To assess renal glomerular safety by measuring change in SCr from baseline to week 12 by randomized study group;
|
Baseline and week 12
|
Change in SCr From Baseline to Week 24.
Time Frame: Baseline and week 24
|
To assess renal glomerular safety by measuring change in SCr from baseline to week 24 by randomized study group;
|
Baseline and week 24
|
Change in SCr From Baseline to Week 48.
Time Frame: Baseline and week 48
|
To assess renal glomerular safety by measuring change in SCr from baseline to week 48 by randomized study group;
|
Baseline and week 48
|
Change From Baseline to Week 48 in Glucose Homeostasis (Fasting Insulin)
Time Frame: Baseline and 48 weeks
|
Baseline and 48 weeks
|
|
Change From Baseline to Week 48 in Glucose Homeostasis (Fasting Glucose)
Time Frame: Baseline and week 48
|
Baseline and week 48
|
|
Change From Baseline to Week 48 in Glucose Homeostasis (Homeostasis Model Assessment of Insulin Resistance (HOMA-IR))
Time Frame: Baseline and week 48
|
HOMA-IR is calculated as fasting glucose (mg/dL) X fasting glucose (uIU/mL) / 405.
An increase in HOMA-IR means that an individual has become more resistant (less sensitive) to the effects of insulin and thus would be a negative outcome.
A reduction in HOMA-IR means that an individual has become more sensitive to the effects of insulin and would be considered a positive outcome.There are no set minimum or maximum scores for HOMA-IR, since it is based on measurements of insulin and glucose, the assays for which may vary.
Several studies suggest a cut-off of >2 for any insulin resistance, but "normal" values appear to vary greatly by population (https://www.mdcalc.com/homa-ir-homeostatic-model-assessment-insulin-resistance).
|
Baseline and week 48
|
Change From Baseline to Week 12 in Serum Calcium (SCa)
Time Frame: Baseline and wk 12
|
Baseline and wk 12
|
|
Change From Baseline to Week 24 in Serum Calcium (SCa)
Time Frame: 24 weeks
|
24 weeks
|
|
Change From Baseline to Week 48 in Serum Calcium (SCa)
Time Frame: Baseline and wk 48
|
Baseline and wk 48
|
|
Change From Baseline to Week 12 in CTX
Time Frame: Baseline and week 12
|
Baseline and week 12
|
|
Change From Baseline to Week 24 in CTX
Time Frame: Baseline and week 24
|
Baseline and week 24
|
|
Change From Baseline to Week 48 in CTX
Time Frame: Baseline and week 48
|
Baseline and week 48
|
|
Change From Baseline to Week 12 in OC
Time Frame: Baseline and week 12
|
Baseline and week 12
|
|
Change From Baseline to Week 24 in OC
Time Frame: Baseline and week 24
|
Baseline and week 24
|
|
Change From Baseline to Week 48 in OC
Time Frame: Baseline and wk 48
|
Baseline and wk 48
|
|
Change From Baseline to Week 12 in BAP
Time Frame: Baseline and wk 12
|
Baseline and wk 12
|
|
Change From Baseline to Week 24 in BAP
Time Frame: Baseline and wk 24
|
Baseline and wk 24
|
|
Change From Baseline to Week 48 in BAP
Time Frame: Baseline and wk 48
|
Baseline and wk 48
|
|
Change From Baseline to Week 12 in FGF23
Time Frame: Baseline and wk 12
|
Baseline and wk 12
|
|
Change From Baseline to Week 24 in FGF23
Time Frame: Baseline and wk 24
|
Baseline and wk 24
|
|
Change From Baseline to Week 48 in FGF23
Time Frame: Baseline and wk 48
|
Baseline and wk 48
|
|
Change From Baseline to Week 12 in PTH
Time Frame: Baseline and wk 12
|
Baseline and wk 12
|
|
Change From Baseline to Week 24 in PTH
Time Frame: Baseline and wk 24
|
Baseline and wk 24
|
|
Change From Baseline to Week 48 in PTH
Time Frame: Baseline and wk 48
|
Baseline and wk 48
|
|
Change From Baseline to Week 12 in Actual Free 1,25-OHD
Time Frame: Baseline and wk 12
|
Vitamin D serum concentration (1,25 (OH)DTotal) (pmol/L) multiplied by F times 1,000, where F is defined as F = 1/(1 + Kd * [VDBP] + Ka *[albumin]) where the binding constant for VDBP = Kd = 4.2 x 107 M-1, and for albumin is Ka = 5.4 x 104 M-1 and the concentrations of VDBP and albumin are in moles/L
|
Baseline and wk 12
|
Change From Baseline to Week 24 in Actual Free 1,25-OHD
Time Frame: Baseline and wk 24
|
Vitamin D serum concentration (1,25 (OH)DTotal) (pmol/L) multiplied by F times 1,000, where F is defined as F = 1/(1 + Kd * [VDBP] + Ka *[albumin]) where the binding constant for VDBP = Kd = 4.2 x 107 M-1, and for albumin is Ka = 5.4 x 104 M-1 and the concentrations of VDBP and albumin are in moles/L
|
Baseline and wk 24
|
Change From Baseline to Week 48 in Actual Free 1,25-OHD
Time Frame: Baseline and wk 48
|
Vitamin D serum concentration (1,25 (OH)DTotal) (pmol/L) multiplied by F times 1,000, where F is defined as F = 1/(1 + Kd * [VDBP] + Ka *[albumin]) where the binding constant for VDBP = Kd = 4.2 x 107 M-1, and for albumin is Ka = 5.4 x 104 M-1 and the concentrations of VDBP and albumin are in moles/L
|
Baseline and wk 48
|
Change From Baseline to Week 12 in 1,25-OHD
Time Frame: Baseline and wk 12
|
Baseline and wk 12
|
|
Change From Baseline to Week 24 in 1,25-OHD
Time Frame: Baseline and wk 24
|
Baseline and wk 24
|
|
Change From Baseline to Week 48 in 1,25-OHD
Time Frame: Baseline and wk 48
|
Baseline and wk 48
|
|
Change From Baseline to Week 12 in 25-OHD
Time Frame: Baseline and wk 12
|
Baseline and wk 12
|
|
Change From Baseline to Week 24 in 25-OHD
Time Frame: Baseline and wk 24
|
Baseline and wk 24
|
|
Change From Baseline to Week 48 in 25-OHD
Time Frame: Baseline and wk 48
|
Baseline and wk 48
|
|
Change From Baseline to Week 12 in TRP %
Time Frame: Baseline and wk 12
|
Baseline and wk 12
|
|
Change From Baseline to Week 24 in TRP %
Time Frame: Baseline and wk 24
|
Baseline and wk 24
|
|
Change From Baseline to Week 48 in TRP %
Time Frame: Baseline and wk 48
|
Baseline and wk 48
|
|
Change From Baseline to Week 12 in SPO4
Time Frame: Baseline and wk 12
|
Baseline and wk 12
|
|
Change From Baseline to Week 24 in SPO4
Time Frame: Baseline and wk 24
|
Baseline and wk 24
|
|
Change From Baseline to Week 48 in SPO4
Time Frame: Baseline and wk 48
|
Baseline and wk 48
|
|
Change From Baseline to Week 12 in UCa/Ucr
Time Frame: Baseline and wk 12
|
Baseline and wk 12
|
|
Change From Baseline to Week 24 in UCa/Ucr
Time Frame: Baseline and wk 24
|
Baseline and wk 24
|
|
Change From Baseline to Week 48 in UCa/Ucr
Time Frame: Baseline and wk 48
|
Baseline and wk 48
|
|
Change in Estimated GFR From Baseline to Week 12.
Time Frame: Baseline and wk 12
|
To assess renal glomerular safety by measuring change in estimated GFR from baseline to week 12 by randomized study group. eGFR calculated by the CKD-Epi equation for subjects >=18 years of age, and by bedside Schwartz formula for subjects <18 years of age |
Baseline and wk 12
|
Change in Estimated GFR From Baseline to Week 24.
Time Frame: Baseline and wk 24
|
To assess renal glomerular safety by measuring change in estimated GFR from baseline to week 24 by randomized study group;
|
Baseline and wk 24
|
Change in Estimated GFR From Baseline to Week 48.
Time Frame: Baseline and wk 48
|
To assess renal glomerular safety by measuring change in estimated GFR from baseline to week 48 by randomized study group;
|
Baseline and wk 48
|
Change in UGluc From Baseline to Week 48
Time Frame: Baseline and wk 48
|
To assess renal tubular function by measuring change in urine glucose (UGluc) by randomized study group;
|
Baseline and wk 48
|
Change in URBP/UCr Ratio From Baseline to Week 48
Time Frame: Baseline and wk 48
|
To assess renal tubular function by measuring change in urine retinol binding protein to urine creatinine (URBP/UCr) ratio by randomized study group;
|
Baseline and wk 48
|
Change in UB2MG From Baseline to Week 48
Time Frame: Baseline and wk 48
|
To assess renal tubular function by measuring change in urine beta-2 microglobulin (UB2MG) by randomized study group;
|
Baseline and wk 48
|
Change in UProt/ UCr Ratio From Baseline to Week 48
Time Frame: Baseline and wk 48
|
To assess renal tubular function by measuring change in urinary protein to creatinine ratio by randomized study group;
|
Baseline and wk 48
|
25-OHD Serum Concentration by Randomized Study Group at Week 12
Time Frame: Week 12
|
Week 12
|
|
25-OHD Serum Concentration by Randomized Study Group at Week 24
Time Frame: Week 24
|
Week 24
|
|
25-OHD Serum Concentration by Randomized Study Group at Week 48
Time Frame: Week 48
|
Week 48
|
|
Effect of Concurrent Treatment With Efavirenz on 25-OHD Serum Concentration: Concentration at Baseline by Efavirenz Use
Time Frame: Baseline
|
Mean Vitamin D serum concentration (25-(OH)D) Total) in those with efavirenz use vs. those without efavirenz use
|
Baseline
|
Effect of Concurrent Treatment With Efavirenz on 25-OHD Serum Concentration: Concentration at Week 48 by Efavirenz Use
Time Frame: Week 48
|
Mean Vitamin D serum concentration (25-(OH)D) Total) in those with efavirenz use vs. those without efavirenz use
|
Week 48
|
Effect of Concurrent Treatment With Efavirenz on 25-OHD Serum Concentration: Change in Concentration From Baseline to Week 48 by Efavirenz Use
Time Frame: Baseline and wk 48
|
Mean Vitamin D serum concentration (25-(OH)D) Total) in those with efavirenz use vs. those without efavirenz use
|
Baseline and wk 48
|
Effect of Concurrent Treatment With Ritonavir on 25-OHD Serum Concentration: Concentration at Baseline by Ritonavir Use
Time Frame: Baseline
|
Mean Vitamin D serum concentration (25-(OH)D) Total) in those with ritonavir use vs. those without ritonavir use
|
Baseline
|
Effect of Concurrent Treatment With Ritonavir on 25-OHD Serum Concentration: Concentration at Week 48 by Ritonavir Use
Time Frame: Week 48
|
Mean Vitamin D serum concentration (25-(OH)D) Total) in those with ritonavir use vs. those without ritonavir use
|
Week 48
|
Effect of Concurrent Treatment With Ritonavir on 25-OHD Serum Concentration: Change in Concentration From Baseline to Week 48 by Ritonavir Use
Time Frame: Baseline and wk 48
|
Mean Vitamin D serum concentration (25-(OH)D) Total) in those with ritonavir use vs. those without ritonavir use
|
Baseline and wk 48
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Peter Havens, MD, MACC Fund Research Center
Publications and helpful links
General Publications
- Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Harris DR, Price G, Baker A, Meyer WA 3rd, Wilson CM, Hazra R, Kapogiannis BG, Mulligan K; Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 109 Study Team. Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial. Clin Infect Dis. 2018 Jan 6;66(2):220-228. doi: 10.1093/cid/cix753.
- Havens PL, Long D, Schuster GU, Gordon CM, Price G, Wilson CM, Kapogiannis BG, Mulligan K, Stephensen CB; Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 117 and 109 study teams. Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone. Antivir Ther. 2018;23(7):623-628. doi: 10.3851/IMP3269. Epub 2018 Sep 27.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Slow Virus Diseases
- HIV Infections
- Infections
- Acquired Immunodeficiency Syndrome
- Physiological Effects of Drugs
- Micronutrients
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Vitamin D
- Cholecalciferol
- Vitamins
- Ergocalciferols
Other Study ID Numbers
- ATN 109 Version 2.0
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infection
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Sociedad Andaluza de Enfermedades InfecciosasConsejeria de Salud. Junta de Andalucia. SpainCompletedHIV Infection | HIV-1 InfectionSpain
-
Allegheny Singer Research Institute (also known...Active, not recruitingHIV Infections | HIV-1-infection | HIV I InfectionUnited States
-
Beckman Coulter, Inc.CompletedHIV I Infection | HIV-2 InfectionFrance
-
Rockefeller UniversityCompletedHIV Infection | Healthy Volunteers | HIV-1 InfectionUnited States
-
Erasmus Medical CenterRecruitingHIV Infections | HIV-1-infection | HIV-2 InfectionNetherlands
-
Erasmus Medical CenterActive, not recruitingHIV Infections | HIV-1-infection | HIV-2 InfectionNetherlands
-
AIDS Healthcare FoundationUniversity of California, Los AngelesCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Northwestern UniversityPfizer; Tibotec, IncCompletedHIV Infections | HIV-1 InfectionUnited States
Clinical Trials on Vitamin D3 50,000 IU
-
Hayat Pharmaceutical Co. PLCUnknownVitamin D DeficiencyJordan
-
Hayat Pharmaceutical Co. PLCJordan University of Science and TechnologyCompletedPolycystic Ovary Syndrome | Hypovitaminosis DJordan
-
University of California, San FranciscoCompleted
-
Nationwide Children's HospitalOhio State UniversityUnknownVitamin D Deficiency | AsthmaUnited States
-
Rutgers UniversityCompleted
-
Emory UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
University of Alabama at BirminghamCompletedUrinary Incontinence | Vitamin D DeficiencyUnited States
-
Brigham and Women's HospitalNational Center for Maternal and Child Health Research, Mongolia; Zuun Kharaa...CompletedVitamin D Deficiency | PregnancyMongolia
-
Green Cross CorporationCompletedHepatitis B InfectionKorea, Republic of
-
Medical University of South CarolinaEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted